- Home
- DXYZ vs ALDX Comparison
DXYZ vs ALDX Comparison
Compare DXYZ & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- ALDX
- Stock Information
- Founded
- DXYZ N/A
- ALDX 2004
- Country
- DXYZ
- ALDX United States
- Employees
- DXYZ N/A
- ALDX N/A
- Industry
- DXYZ
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- DXYZ
- ALDX Health Care
- Exchange
- DXYZ Nasdaq
- ALDX Nasdaq
- Market Cap
- DXYZ 313.1M
- ALDX 313.4M
- IPO Year
- DXYZ 2024
- ALDX 2014
- Fundamental
- Price
- DXYZ $28.02
- ALDX $5.60
- Analyst Decision
- DXYZ
- ALDX Strong Buy
- Analyst Count
- DXYZ 0
- ALDX 2
- Target Price
- DXYZ N/A
- ALDX $9.50
- AVG Volume (30 Days)
- DXYZ N/A
- ALDX 715.8K
- Earning Date
- DXYZ N/A
- ALDX 11-06-2025
- Dividend Yield
- DXYZ N/A
- ALDX N/A
- EPS Growth
- DXYZ N/A
- ALDX N/A
- EPS
- DXYZ N/A
- ALDX N/A
- Revenue
- DXYZ N/A
- ALDX N/A
- Revenue This Year
- DXYZ N/A
- ALDX N/A
- Revenue Next Year
- DXYZ N/A
- ALDX $36.23
- P/E Ratio
- DXYZ N/A
- ALDX N/A
- Revenue Growth
- DXYZ N/A
- ALDX N/A
- 52 Week Low
- DXYZ N/A
- ALDX $1.14
- 52 Week High
- DXYZ N/A
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- DXYZ 52.51
- ALDX 59.73
- Support Level
- DXYZ $28.01
- ALDX $5.13
- Resistance Level
- DXYZ $32.93
- ALDX $5.78
- Average True Range (ATR)
- DXYZ 2.11
- ALDX 0.23
- MACD
- DXYZ 0.63
- ALDX 0.06
- Stochastic Oscillator
- DXYZ 59.87
- ALDX 84.00
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.